Enzepi

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Download Risalah maklumat (PIL)
14-08-2017
Download Ciri produk (SPC)
14-08-2017
Download Laporan Penilaian Awam (PAR)
19-07-2016

Bahan aktif:

pancreas powder

Boleh didapati daripada:

Allergan Pharmaceuticals International Ltd

Kod ATC:

A09AA02

INN (Nama Antarabangsa):

pancreas powder

Kumpulan terapeutik:

Digestives, incl. enzymes

Kawasan terapeutik:

Exocrine Pancreatic Insufficiency

Tanda-tanda terapeutik:

Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).Enzepi is indicated in infants, children, adolescents and adults.

Ringkasan produk:

Revision: 1

Status kebenaran:

Withdrawn

Tarikh kebenaran:

2016-06-29

Risalah maklumat

                                32
PACKAGE LEAFLET
Medicinal product no longer authorised
33
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ENZEPI 5,000 UNITS GASTRO-RESISTANT HARD CAPSULES
ENZEPI 10,000 UNITS GASTRO-RESISTANT HARD CAPSULES
ENZEPI 25,000 UNITS GASTRO-RESISTANT HARD CAPSULES
ENZEPI 40,000 UNITS GASTRO-RESISTANT HARD CAPSULES
Pancreas powder
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Enzepi is and what it is used for
2.
What you need to know before you take Enzepi
3.
How to take Enzepi
4.
Possible side effects
5.
How to store Enzepi
6.
Contents of the pack and other information
1.
WHAT ENZEPI IS AND WHAT IT IS USED FOR
Enzepi
is a pancreatic enzyme replacement medicine for people whose bodies do
not make enough of
enzymes to digest food.
Enzepi contains a mixture of natural digestive enzymes which are used
to digest food. These include lipases
for digesting fat, proteases for digesting protein and amylases for
digestions carbohydrates. The enzymes are
taken from pig pancreas glands.
Enzepi is for use by adults, adolescents, children and infants with
‘exocrine pancreatic insufficiency’, a
condition that makes the body less able to break down and digest food.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENZEPI
DO NOT TAKE ENZEPI
-
if you are allergic to the active subtance or any of the other
ingredients of this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Enzepi
if you have ever had gout, kidney disease, or high uric acid levels in
your blood (hyperur
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Enzepi 5,000 units gastro-resistant hard capsules
Enzepi 10,000 units gastro-resistant hard capsules
Enzepi 25,000 units gastro-resistant hard capsules
Enzepi 40,000 units gastro-resistant hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Enzepi 5,000 units gastro-resistant hard capsules
One capsule contains 39.8 mg of pancreas powder of porcine origin
including the following enzymatic
activities:
lipolytic activity:
5,000 units*,
amylolytic activity:
not less than
1,600 units*,
proteolytic activity:
not less than
130 units*.
Enzepi 10,000 units gastro-resistant hard capsules
One capsule contains 83.7 mg of pancreas powder of porcine origin
including the following enzymatic
activities:
lipolytic activity:
10,000 units*,
amylolytic activity:
not less than
3,200 units*,
proteolytic activity:
not less than
270 units*.
Enzepi 25,000 units gastro-resistant hard capsules
One capsule contains 209.3 mg of pancreas powder of porcine origin
including the following enzymatic
activities:
lipolytic activity:
25,000 units*,
amylolytic activity:
not less than
4,800 units*,
proteolytic activity:
not less than
410 units*.
Enzepi 40,000 units gastro-resistant hard capsules
One capsule contains 334.9 mg of pancreas powder of porcine origin
including the following enzymatic
activities:
lipolytic activity:
40,000 units*,
amylolytic activity:
not less than
7,800 units*,
proteolytic activity:
not less than
650 units*.
* Ph. Eur. units
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant hard capsule.
Enzepi 5,000 units gastro-resistant hard capsules
Hard capsules with a white opaque cap and a white opaque body, printed
with “Enzepi 5” and containing
light-brown gastro-resistant granules.
Medicinal product no longer authorised
3
Enzepi 10,000 units gastro-resistant hard capsules
Hard capsule with a yellow opaque cap and a white opaque body, printed
with “Enzepi 10” an
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 14-08-2017
Ciri produk Ciri produk Bulgaria 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 19-07-2016
Risalah maklumat Risalah maklumat Sepanyol 14-08-2017
Ciri produk Ciri produk Sepanyol 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 19-07-2016
Risalah maklumat Risalah maklumat Czech 14-08-2017
Ciri produk Ciri produk Czech 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Czech 19-07-2016
Risalah maklumat Risalah maklumat Denmark 14-08-2017
Ciri produk Ciri produk Denmark 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 19-07-2016
Risalah maklumat Risalah maklumat Jerman 14-08-2017
Ciri produk Ciri produk Jerman 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 19-07-2016
Risalah maklumat Risalah maklumat Estonia 14-08-2017
Ciri produk Ciri produk Estonia 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 19-07-2016
Risalah maklumat Risalah maklumat Greek 14-08-2017
Ciri produk Ciri produk Greek 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Greek 19-07-2016
Risalah maklumat Risalah maklumat Perancis 14-08-2017
Ciri produk Ciri produk Perancis 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 19-07-2016
Risalah maklumat Risalah maklumat Itali 14-08-2017
Ciri produk Ciri produk Itali 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Itali 19-07-2016
Risalah maklumat Risalah maklumat Latvia 14-08-2017
Ciri produk Ciri produk Latvia 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 19-07-2016
Risalah maklumat Risalah maklumat Lithuania 14-08-2017
Ciri produk Ciri produk Lithuania 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 19-07-2016
Risalah maklumat Risalah maklumat Hungary 14-08-2017
Ciri produk Ciri produk Hungary 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 19-07-2016
Risalah maklumat Risalah maklumat Malta 14-08-2017
Ciri produk Ciri produk Malta 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Malta 19-07-2016
Risalah maklumat Risalah maklumat Belanda 14-08-2017
Ciri produk Ciri produk Belanda 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 19-07-2016
Risalah maklumat Risalah maklumat Poland 14-08-2017
Ciri produk Ciri produk Poland 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Poland 19-07-2016
Risalah maklumat Risalah maklumat Portugis 14-08-2017
Ciri produk Ciri produk Portugis 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 19-07-2016
Risalah maklumat Risalah maklumat Romania 14-08-2017
Ciri produk Ciri produk Romania 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Romania 19-07-2016
Risalah maklumat Risalah maklumat Slovak 14-08-2017
Ciri produk Ciri produk Slovak 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 19-07-2016
Risalah maklumat Risalah maklumat Slovenia 14-08-2017
Ciri produk Ciri produk Slovenia 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 19-07-2016
Risalah maklumat Risalah maklumat Finland 14-08-2017
Ciri produk Ciri produk Finland 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Finland 19-07-2016
Risalah maklumat Risalah maklumat Sweden 14-08-2017
Ciri produk Ciri produk Sweden 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 19-07-2016
Risalah maklumat Risalah maklumat Norway 14-08-2017
Ciri produk Ciri produk Norway 14-08-2017
Risalah maklumat Risalah maklumat Iceland 14-08-2017
Ciri produk Ciri produk Iceland 14-08-2017
Risalah maklumat Risalah maklumat Croat 14-08-2017
Ciri produk Ciri produk Croat 14-08-2017
Laporan Penilaian Awam Laporan Penilaian Awam Croat 19-07-2016

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen